Halsey Associates Inc. CT Acquires New Stake in Iqvia Holdings Inc (IQV)

Halsey Associates Inc. CT acquired a new stake in shares of Iqvia Holdings Inc (NYSE:IQV) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 186,167 shares of the medical research company’s stock, valued at approximately $18,226,000. Iqvia comprises 3.1% of Halsey Associates Inc. CT’s holdings, making the stock its 8th largest position. Halsey Associates Inc. CT owned approximately 0.09% of Iqvia as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Exxonmobil Investment Management Inc. TX acquired a new position in shares of Iqvia during the fourth quarter valued at about $2,266,000. DnB Asset Management AS acquired a new position in Iqvia in the fourth quarter worth about $8,813,000. First Citizens Bank & Trust Co. acquired a new position in Iqvia in the fourth quarter worth about $1,067,000. Franklin Street Advisors Inc. NC acquired a new position in Iqvia in the fourth quarter worth about $7,446,000. Finally, Nisa Investment Advisors LLC acquired a new position in Iqvia in the fourth quarter worth about $920,000. 92.33% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of Iqvia Holdings Inc (IQV) traded down $0.15 during midday trading on Tuesday, reaching $104.61. 24,241 shares of the company traded hands, compared to its average volume of 1,140,307. Iqvia Holdings Inc has a fifty-two week low of $76.80 and a fifty-two week high of $110.67. The firm has a market capitalization of $22,012.07, a price-to-earnings ratio of 17.32, a P/E/G ratio of 2.70 and a beta of 0.64. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.19 and a quick ratio of 1.19.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). Iqvia had a net margin of 13.44% and a return on equity of 13.03%. The business had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the prior year, the company earned $1.09 earnings per share. The company’s quarterly revenue was up 10.7% on a year-over-year basis. equities research analysts anticipate that Iqvia Holdings Inc will post 2.84 earnings per share for the current fiscal year.

IQV has been the subject of several recent research reports. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $112.00 price target for the company in a research report on Thursday, January 18th. SunTrust Banks raised shares of Iqvia from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. Evercore ISI initiated coverage on shares of Iqvia in a research report on Thursday, January 18th. They issued an “outperform” rating and a $112.00 price target for the company. Mitsubishi UFJ Financial Group initiated coverage on shares of Iqvia in a research report on Friday, December 15th. They issued a “neutral” rating and a $112.00 price target for the company. Finally, TheStreet raised shares of Iqvia from a “c+” rating to a “b” rating in a research report on Wednesday, December 13th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $110.02.

In other Iqvia news, Director Michael J. Evanisko sold 816 shares of the stock in a transaction on Monday, March 5th. The shares were sold at an average price of $100.00, for a total value of $81,600.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total transaction of $999,700.00. The disclosure for this sale can be found here. Insiders sold 31,712 shares of company stock worth $3,188,134 over the last 90 days. 6.00% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Halsey Associates Inc. CT Acquires New Stake in Iqvia Holdings Inc (IQV)” was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thestockobserver.com/2018/03/20/halsey-associates-inc-ct-acquires-new-stake-in-iqvia-holdings-inc-iqv.html.

Iqvia Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply